

**Southern Sleep Society 43rd Annual Meeting – A Virtual Event
April 23-25, 2021
Speaker and Planner Disclosures and Resolutions**

Statement of Need

The need for these activities has been determined based on identifying professional practice gaps, as well as review of previous course evaluations and member surveys. The educational content was developed based on current issues and topic trends provided by the Southern Sleep Society leadership and membership.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The American Academy of Sleep Medicine and The Southern Sleep Society. The American Academy of Sleep Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Disclosure Statement

As an education provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Academy of Sleep Medicine must ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All product developers, planners, and speakers are expected to disclose any relevant financial interest or other relationships held by the individual, or members of their family, that are relevant to the presentation over the preceding twelve months with (1) manufacturers of any commercial products and/or providers of commercial services, (2) any commercial supporters, (3) any off-label or investigational uses of products. The individual is also required to disclose if he/she has no relationships with any manufacturers, products or services that are relevant to the presentation. The ACCME Standards for Commercial Support require accredited CME providers to resolve all identified potential conflicts of interest with any individual in a position to influence and/or control the content of CME activities prior to the education activity being delivered to learners.

Resolution of Conflicts of Interest

AASM has implemented mechanisms to identify and mitigate conflicts of interest for all individuals in a position to control content, prior to the planning and implementation of these CME activities. **Course Chair(s) review the COI declarations to satisfy no commercial bias exists.** All Conflict of Interest Disclosures are provided to participants prior to start of the activity.

Faculty Disclosures:

The following Southern Sleep Society faculty members have no relevant relationships with any commercial interests to disclose:

Timothy Morgenthaler, MD, Byron Jamerson, RPSGT, CCSH, Kristina Weaver, EMT-P, RPSGT, Laura Linley, RPSGT, RST, CRT, Patrick Sorenson, RPSGT, Joel Porquez, RPSGT, RST, Patrick Sorenson, RPSGT, Debbie Akers, RRT, RPSGT, Marilyn Swick, RPSGT, Timothy Morgenthaler, MD, Peter C. Gay, MD, Nilgun Giray, MD, PhD, Carlos Scheck, MD, Amir Sharafkhaneh, MD, Romy Hoque, MD, Mary Rose, PsyD, DBSM, CBSM, Michael Nadorff, PhD, Shariar Shahzeidi, MD, Ruckshanda Majid, Md. Kathy Richards, PhD, RN, FAAN, Gregory Carter, MD, PhD, Dave Balachandran, MD, Lilit Sargsyan, MD, Ashley Knox, MS, APRN, FNP-C, Tamara De Lumban, APRN.

The following faculty members disclosed the following:

Tammy Muth-Davis, BS, RPSGT, RRT disclosed:
Stock/Stockholder: Own Stock in ResMed, Salary: Employee of Manufacture - ResMed.

Donald Bliwise, PhD disclosed:
Consultant: Merck, Ferring, Eisai, Huxley.

Southern Sleep Society 43rd Annual Meeting – A Virtual Event

April 23-25, 2021

Speaker and Planner Disclosures and Resolutions

Citations:

1. Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, Stevens J, Lines C, Michelson D. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. *Alzheimers Dement*. 2020 Mar;16(3):541-551.
2. Bliwise DL, Foley DJ, Vitiello MV et al. Nocturia and sleep disturbance in the elderly. *Sleep Medicine* 10: 2009: 540-8."

David Rye, MD disclosed:

Grant/Research Support: Research Support: ACTIVE NS113912 Rye (Co-I) – 7.5% effort (09-01-2019-8/31/2024) Mechanisms and regulation of brain iron uptake Project Narrative: This study employs cell and animal models and human biospecimens (e.g., cerebrospinal fluids) to investigate the molecular mechanisms governing iron transport across the blood-brain-barrier (i.e., into and out of the brain). NS111280 Rye (Co-I) – 5% effort (08/01/2019 – 7/31/2024) Antibiotic-mediated improvements in vigilance: mechanisms of action of clarithromycin in hypersomnia syndromes Project Narrative: This study investigates the mechanisms inclusive of brain circuits underlying clinical relevant hypersomnia/somnolence refractory to traditional wake promoting drugs such as psychostimulants, but, responsive to the macrolide antibiotic clarithromycin.

Investigational Device/Drug: Dr. Rye is a co-inventor on United States Patent Application 20110028418 that describes the use of GABA-A receptor antagonists for the treatment of excessive sleepiness and sleep disorders associated with excessive sleepiness. Direct Link: <http://emoryott.technologypublisher.com/technology/2291>. This has provided rationale for two registered, multi-center clinical trials now completed (ARISE-1 and ARISE-2) for the treatment of idiopathic hypersomnia.

Consultant: Jazz Pharmaceuticals, Takeda Pharmaceuticals, Harmony Biosciences, Eisai Pharmaceuticals, Major League Baseball, Garland, Samuel, & Loeb, P.C.

Stock/Stockholder: Family: Sage Therapeutics, Roche Holdings

Royalties: Dr. Rye has received royalties per a licensing agreement between Emory University and Balance Therapeutics describing the use of GABA-A receptor antagonists for the treatment of excessive sleepiness and sleep disorders associated with excessive sleepiness. Dr. Rye has also received royalties per a licensing agreement between Emory University and Expansion therapeutics describing use of GABA-A receptor antagonists for the treatment of excessive sleepiness and associated (cognitive) disorders in myotonic dystrophy.

Intellectual property: Dr. Rye is a co-inventor on United States Patent Application 20110028418 that describes the use of GABA-A receptor antagonists for the treatment of excessive sleepiness and sleep disorders associated with excessive sleepiness. Direct Link: <http://emoryott.technologypublisher.com/technology/2291>

Citations:

1. Trotti LM, Saini P, Koola C, LaBarbera V, Bliwise, DL, Rye DB (2016) Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients. *J Clin Sleep Med* 12(10):1389-1394. doi: 10.5664/jcsm.6196.
2. Rye DB, Bliwise DL, Parker K, Trotti LM, Saini P, Fairley J, Freeman A, Garcia PS, Owens MJ, Ritchie JC, Jenkins A (2012) Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors. *Sci Transl Med*. 21;4(161):161ra151. "

Arthur Walters, MD disclosed:

Grant/Research Support: (1) Xenoport/Arbor grant support for study to determine the pharmacokinetic properties and therapeutic efficacy of gabapentin enacarbil in Restless Legs Syndrome (2)NIH ROI grant to determine the role of body metals in Restless Legs Syndrome. (3) Grant from MundiPharma to construct an opiate receptor knock out mouse model of Restless Legs Syndrome.

Consultant: (1) Member of the Medical Advisory Board of the Restless Legs Syndrome Foundation (RLSF). (2) Member of the Executive Committee of the International Restless Legs Syndrome Study Group (IRLSSG).

Citations:

1. Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty S, Kavey N. Successful treatment of the idiopathic restless legs syndrome in a randomized double blind trial of oxycodone versus placebo. *Sleep* 16:327-332, 1993.
2. Walters AS, Ondo WG, Zhu W, Le W. Does the endogenous opiate system play a role in the Restless Legs Syndrome?: A pilot post-mortem study. *Journal of the Neurological Sciences* 279: 62-65; 2009.

Southern Sleep Society 43rd Annual Meeting – A Virtual Event

April 23-25, 2021

Speaker and Planner Disclosures and Resolutions

3. Lyu S, DeAndrade M, Mueller S, Oksche A, Walters AS, Li Y. Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in-vivo opioid receptors knockout mouse: Implications for the Restless Legs Syndrome. Behavioural Brain Research (2019). <https://doi.org/10.1016/j.bbr.2019.> "

Margaret Hovda, MD disclosed:

Speakers' bureau: Inspire Medical Systems.

Citations:

1. Thaler et al. ""Results of the ADHERE Upper Airway Stimulation Registry and predictors of Therapy Efficacy."" Laryngoscope. 130. (2020): 1333-1338.
2. Woodson et al. ""Upper Airway Stimulation for Obstructive Sleep Apnea: 5 year Outcomes."" Otolaryngology - Head and Neck Surgery. 2018 (1 - 9).
3. Strollo et al. ""Upper-Airway Stimulation for Obstructive Sleep Apnea. N Engl J Med. 370. (2014): 139 - 149."

Lynn Marie Trotti, MD disclosed:

Other financial/material support: Funds to my institution (none to me) for the pitolisant EAP.

Investigational Device/Drug: IND for flumazenil for hypersomnia.

Citations:

1. Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, et al. A Randomized Study of Solriamfetol for Excessive Sleepiness in Narcolepsy. Ann Neurol. 2019;85(3):359-70.
2. Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. The Lancet Neurology. 2013;12(11):1068-75. "

Asim Roy, MD disclosed:

Grant/Research Support: Jazz, Inspire, Eisai, Avadel, Suven, Takeda, Harmony, Nyxoah

Speakers' bureau: Jazz Pharma, Eisai, Inspire, Harmony Bioscience, Vanda

Citation:

Patrick J. Strollo, Jr., M.D., ""Upper-Airway Stimulation for Obstructive Sleep Apnea"". N Engl J Med 2014; 370:139-149"

Planner Disclosures:

The Southern Sleep Society planners have no relevant relationships with any commercial interests to disclose:

Marietta Bibbs, RPSGT (Chair)

Mary Rose, PsyD

Denise Sharon, MD, PhD